A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4*
暂无分享,去创建一个
T. Baillie | T. Rushmore | K. Korzekwa | R. Dai | M. Shou | D. Cui
[1] L. Wienkers,et al. Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[2] R. Miller,et al. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[3] J. Halpert,et al. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. , 2000, The Journal of pharmacology and experimental therapeutics.
[4] G. Miller,et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.
[5] Renke Dai,et al. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site , 1999 .
[6] J. Halpert,et al. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.
[8] J. Liu,et al. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. , 1998, Archives of biochemistry and biophysics.
[9] A Carlsson,et al. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. , 1997, Life sciences.
[10] A. P. Koley,et al. Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.
[11] F. Guengerich,et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.
[12] Susan E. Wilson,et al. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E‐3174 , 1996, Clinical pharmacology and therapeutics.
[13] D W Nebert,et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.
[14] S. Waldman,et al. Losartan Does Not Affect the Pharmacokinetics and Pharmacodynamics of Warfarin , 1995, Journal of clinical pharmacology.
[15] H. Yamazaki,et al. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. , 1995, Chemical research in toxicology.
[16] P. Chakravarty,et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[17] F. Guengerich,et al. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[18] M. Waterman,et al. Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research , 1994, Ernst Schering Research Foundation Workshop.
[19] R. Brodell,et al. A practical approach to antibiotic treatment in women taking oral contraceptives. , 1994, Journal of the American Academy of Dermatology.
[20] S. Sligar,et al. Cytochrome P450 and Aromatic Bases: A 1H NMR Study , 1994 .
[21] D. Kroetz,et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.
[22] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[23] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[24] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[25] S. Imaoka,et al. Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. , 1992, Biochemistry.
[26] T. Shimada,et al. Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. , 1992, Chemical research in toxicology.
[27] S. Nelson,et al. Activation of acetaminophen-reactive metabolite formation by methylxanthines and known cytochrome P-450 activators. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[28] P. Timmermans,et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.
[29] G. Lucier,et al. Involvement of cytochrome P-450c in alpha-naphthoflavone metabolism by rat liver microsomes. , 1990, Molecular pharmacology.
[30] F. Gonzalez,et al. The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.
[31] E. Johnson,et al. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. , 1988, Molecular pharmacology.
[32] F. Guengerich. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.
[33] J. Kellis,et al. Inhibition of human estrogen synthetase (aromatase) by flavones. , 1984, Science.
[34] P. Beaune,et al. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. , 1983, Biochemistry.
[35] M. J. Coon,et al. Specificity in the activation and inhibition by flavonoids of benzo[a]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes. , 1981, The Journal of biological chemistry.
[36] M. Huang,et al. Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. , 1981, The Journal of biological chemistry.
[37] H. Bolt,et al. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. , 1977, Acta endocrinologica.
[38] Y. Yasukochi,et al. Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. , 1976, The Journal of biological chemistry.
[39] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1976 .
[40] D. Marquardt. An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .
[41] T. Shimada,et al. The Importance of Cytochrome P450 3A Enzymes in Drug Metabolism , 1994 .
[42] Benveniste,et al. Cytochrome P450 , 1993, Handbook of Experimental Pharmacology.
[43] C. F. Timberlake. The Flavonoids—Advances in Research since 1980: : edited by J. B. Harborne. Chapman & Hall, London and New York, xiii+621 pp. £95. , 1989 .
[44] R. Stewart,et al. Clinically desirable drug interactions. , 1985, Annual review of pharmacology and toxicology.
[45] P. Richardson. The Flavonoids: Advances in Research , 1982 .
[46] F. Wedler. Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady‐state enzyme systems. Author: Irwin H. Segal (University of California, Davis). Published by Wiley‐Interscience, New York, 1975. Price: $24.50. No. of pages: 957 , 1976 .